Six patients (60%) had several potential risk factors that included: accidental omission of pre-medication, injection from a new vial despite appropriate dose reduction, injection during high pollen season, concomitant ACE inhibitor use, uncontrolled asthma, possible error in administration route, and previous history of systemic reactions to SCIT. This evidence concerns the gene ACE and asthma.